Genmab AS (GMAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $31.67B
Last updated: Nov 17, 2026 at 11:06 AM ET
Genmab AS (GMAB) Competitors
The companies most similar to Genmab AS are BeOne Medicines AG (ONC), argenx NV ADR (ARGX) and Insmed (INSM). Genmab AS trades at 35.8x earnings, against a median of 19.3x for the 5 of these companies with a P/E. By market cap, Genmab AS ranks 6th of the 13 companies on this page; Moderna (MRNA) is the largest at $90.38B.
Peer Comparison
GMAB's ROIC of 4.8% is above the peer median of -12.7%, and its revenue growth of 16.1% is below the median of 43.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Genmab AS (GMAB) | $31.67B | 35.8x | 19.2x | 17.0% | 4.8% | 16.1% | 0.00% |
| BeOne Medicines AG (ONC) | $47.58B | 50.0x | 18.7x | 13.9% | 7.5% | 33.8% | 0.00% |
| argenx NV ADR (ARGX) | $60.37B | 33.5x | 6.1x | 31.7% | N/A | 52.1% | 0.00% |
| Insmed Inc (INSM) | $26.58B | N/A | 17.7x | -39.9% | -44.2% | 268.4% | 0.00% |
| Ascendis Pharma AS (ASND) | $18.06B | N/A | 13.5x | 72.9% | 12.4% | 73.0% | 0.00% |
| Revolution Medicines Inc (RVMD) | $37.27B | N/A | 181.6x | 0.0% | -52.1% | -95.2% | 0.00% |
| BridgeBio Pharma Inc (BBIO) | $15.25B | N/A | 16.0x | -59.8% | -33.0% | 192.6% | 0.00% |
| Exelixis Inc (EXEL) | $16.84B | 19.3x | 6.9x | 35.4% | N/A | 10.2% | 0.00% |
| Roivant Sciences Ltd (ROIV) | $28.64B | N/A | 679.3x | 0.0% | N/A | 2136.0% | 0.00% |
| Moderna Inc (MRNA) | $90.38B | N/A | 34.2x | -110.5% | -28.9% | 29.2% | 0.00% |
| Jazz Pharmaceuticals PLC (JAZZ) | $15.50B | 18.4x | 3.3x | 4.4% | 3.5% | 10.4% | 0.00% |
| Royalty Pharma Plc (RPRX) | $39.85B | 12.9x | 11.7x | 25.7% | 7.6% | 13.3% | 1.37% |
| Kymera Therapeutics Inc (KYMR) | $10.89B | N/A | 123.2x | 0.0% | N/A | 466.4% | 0.00% |
| Peer median | $27.61B | 19.3x | 16.9x | 2.2% | -12.7% | 43.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Genmab AS, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| BeOne Medicines AG (ONC) | BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe... | ONC competitors |
| argenx NV ADR (ARGX) | argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases... | ARGX competitors |
| Insmed Inc (INSM) | Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. | INSM competitors |
| Ascendis Pharma AS (ASND) | Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark. | ASND competitors |
| Revolution Medicines Inc (RVMD) | Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted... | RVMD competitors |
| BridgeBio Pharma Inc (BBIO) | BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. | BBIO competitors |
| Exelixis Inc (EXEL) | Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development... | EXEL competitors |
| Roivant Sciences Ltd (ROIV) | Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive... | ROIV competitors |
| Moderna Inc (MRNA) | Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology... | MRNA competitors |
| Jazz Pharmaceuticals PLC (JAZZ) | Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United... | JAZZ competitors |
| Royalty Pharma Plc (RPRX) | Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. | RPRX competitors |
| Kymera Therapeutics Inc (KYMR) | Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down... | KYMR competitors |
Frequently Asked Questions About GMAB
Who are Genmab AS' main competitors?
The companies most similar to Genmab AS include BeOne Medicines AG (ONC), argenx NV ADR (ARGX), Insmed (INSM), Ascendis Pharma AS (ASND) and Revolution Medicines (RVMD), listed from the closest match.
Who is Genmab AS' biggest competitor?
Moderna (MRNA) is the largest of the similar companies at $90.38B; BeOne Medicines AG (ONC) is the closest match by business profile, size, sector and industry.
How does GMAB stock compare with its competitors?
GMAB's P/E is 35.8x against a peer median of 19.3x; its P/S is 19.2x against a peer median of 16.9x; its net margin is 17.0% against a peer median of 2.2%.
Which of Genmab AS' competitors pays a higher dividend?
Genmab AS pays no dividend. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.
Is Genmab AS bigger than its competitors?
No. Genmab AS is 6th by market cap among the 13 companies on this page; the largest is Moderna (MRNA) at $90.38B.
GMAB pages: Overview, Valuation, Competitors